central
venou
obstruct
cvo
rare
dog
clinic
sign
manifest
secondari
vena
caval
obstruct
subcutan
edema
cavitari
effus
intervent
critic
decreas
translumin
pressur
gradient
across
obstruct
minim
sign
refer
cvo
case
record
one
author
ba
retrospect
review
dog
underw
endovascular
intervent
cvo
six
dog
identifi
dog
cranial
vena
caval
thrombosi
follow
cardiopulmonari
bypass
dog
caudal
vena
caval
compress
secondari
neoplasia
endovascular
intervent
includ
direct
local
thrombolysi
balloon
angioplasti
cranial
vena
caval
stent
implant
transatri
stent
implant
dog
endovascular
intervent
result
acut
resolut
cavitari
effus
facial
swell
angiograph
document
improv
venou
return
one
dog
receiv
local
thrombolysi
infus
cathet
begin
day
cvo
recognit
fail
show
clinic
improv
local
thrombolysi
balloon
angioplasti
resolv
cranial
cvo
anoth
dog
perform
within
clinic
recognit
balloon
angioplasti
cranial
vena
caval
stent
implant
resolv
cvo
anoth
dog
howev
recurr
strictur
growth
stent
occur
dog
transatri
stent
implant
resolut
ascit
month
dog
still
aliv
lost
time
effect
endovascular
intervent
resolv
clinic
sign
cvo
dog
approach
intervent
manag
may
necessari
includ
thrombolyt
balloon
angioplasti
vascular
stent
echocardiographi
method
screen
cat
presenc
heart
diseas
howev
sever
factor
affect
echocardiograph
measur
evalu
effect
age
breed
sex
neuter
statu
year
examin
examin
bodi
weight
bw
aortic
ao
left
atrial
la
ventricular
lv
linear
dimens
unsed
normal
pedigre
cat
clinic
data
echocardiograph
examin
unsed
normal
cat
within
pawp
program
conduct
includ
examin
conduct
examin
breed
age
sex
neuter
statu
year
examin
small
effect
p
echocardiograph
variabl
univari
analys
multivari
analys
model
coeffici
determin
r
includ
examin
rang
variabl
remain
multivari
model
echocardiograph
variabl
includ
age
neuter
statu
breed
year
examin
sex
independ
effect
ao
lv
diamet
includ
examin
model
increas
r
rang
varianc
compon
show
examin
contribut
total
varianc
account
contribut
variabl
total
varianc
echocardiograph
variabl
sex
neuter
statu
breed
year
examin
conclus
age
breed
sex
neuter
statu
year
examin
compar
examin
compar
small
effect
la
ao
lv
dimens
suggest
standard
imag
acquisit
measur
warrant
strangl
highli
infecti
upper
respiratori
diseas
high
morbid
rate
financi
burden
anim
health
trust
uk
current
use
identifi
recent
infect
identifi
expos
anim
without
sign
serolog
test
use
surfac
protein
antigen
compos
portion
antigen
sem
antigen
c
capabl
differenti
vaccin
infect
anim
diva
depend
vaccin
use
hypothes
hors
vaccin
strangl
pinnacl
zoeti
base
live
attenu
strain
equi
seroconvert
test
week
annual
revaccin
serum
sampl
hors
mean
year
stabl
strangl
outbreak
year
prior
obtain
time
annual
strangl
vaccin
week
post
vaccin
hors
histori
strangl
mean
medic
record
histori
year
mean
histor
pinnacl
vaccin
antigen
ag
seroconvers
determin
valu
hors
seroconvert
ag
prior
vaccin
seroconvert
ag
c
week
post
vaccin
seroconvert
ag
mean
ag
c
mean
high
rate
seroconvers
antigen
diva
capabl
hors
vaccin
pinnacl
appear
poor
refer
robinson
c
steward
kf
pott
n
et
al
combin
two
serolog
assay
optimis
sensit
specif
identif
streptococcu
equi
subsp
equi
exposur
vet
j
propidium
monoazid
pma
quantit
pcr
qpcr
use
differenti
dna
live
dead
bacteri
cell
pma
enter
nonviabl
cell
leaki
cell
membran
bind
dna
insid
cell
photoactiv
strong
visibl
light
make
unabl
act
templat
pcr
result
quantif
viabl
cell
vitro
studi
success
demonstr
pma
prior
qpcr
sampl
known
coloni
form
unit
streptococci
equi
equi
equi
identifi
known
percentag
heat
kill
viabl
cell
aim
studi
evalu
abil
pma
eqb
triplex
qpcr
differenti
dna
viabl
nonviabl
equi
posit
suspect
posit
clinic
sampl
store
frozen
refriger
posit
suspect
posit
clinic
sampl
determin
via
seei
qpcr
gold
standard
test
use
eqb
triplex
qpcr
without
pma
number
equi
posit
sampl
follow
eqb
pma
pma
eqb
cycl
threshold
count
ct
lower
correspond
seei
suggest
good
target
gene
ct
pma
posit
sampl
higher
correspond
sampl
indic
mixtur
viabl
nonviabl
cell
sampl
low
number
qpcr
pma
posit
sampl
indic
larg
number
sampl
nonviabl
cell
like
due
storag
time
pma
qpcr
use
determin
equi
viabil
test
perform
fresh
sampl
klebsiella
pneumonia
identifi
import
pulmonari
pathogen
hors
recent
hypervirul
k
pneumonia
frequent
hypermucovis
hmv
phenotyp
describ
human
primat
marin
mammal
klebsiella
pneumonia
without
hmv
phenotyp
isol
pulmonari
sampl
five
hors
california
alabama
five
hors
euthan
four
underw
necropsi
examin
primari
pulmonari
lesion
sever
pneumonia
consolid
abscess
thirteen
k
pneumonia
isol
differ
coloni
morpholog
obtain
andor
sampl
five
hors
isol
examin
mucoviscos
use
string
test
ident
confirm
molecularli
virul
gene
profil
character
use
endpoint
pcr
eleven
isol
three
hors
genotyp
gel
electrophoresi
pfge
six
isol
exhibit
hmv
phenotyp
includ
isol
four
five
hors
isol
capsular
type
rmpa
posit
regardless
hmv
phenotyp
pcr
demonstr
ident
profil
isol
posit
fimh
fyua
irod
mrkb
neg
test
gene
examin
pfge
pulsotyp
reveal
isol
two
hors
facil
indistinguish
suggest
hmv
k
pneumonia
may
capabl
transmiss
hors
acquir
common
sourc
infect
isol
third
hors
unrel
hors
isol
indistinguish
one
anoth
hypermucoviscoushypervirul
k
pneumonia
consid
etiolog
agent
sever
pneumonia
hors
enterococcu
duran
gram
cocci
infrequ
associ
diarrhea
human
foal
piglet
puppi
calv
rat
purpos
studi
identifi
pathogen
associ
foal
affect
diarrhea
first
day
foal
farm
interest
thoroughbr
breed
farm
newborn
foal
day
age
develop
diarrhea
previou
year
clinic
affect
foal
clostridium
perfringen
well
clostridium
difficl
detect
fece
despit
use
prophylact
antimicrobi
metronidazol
infecti
control
measur
farm
continu
experi
increas
number
foal
diarrhea
foal
mare
sampl
fece
diagnosi
select
pathogen
day
foal
sampl
submit
hagyard
equin
medic
institut
diagnosi
follow
pathogen
cultur
salmonella
e
coli
aeromona
e
duran
c
perfringen
sampl
also
submit
idexx
pcr
cryptosporidium
clostridium
perfringen
enterotoxin
lawsonia
rotaviru
coronaviru
clostridium
difficl
toxin
b
rhodococcu
equi
salmonella
result
reveal
clear
pattern
select
pathogen
associ
diarrhea
affect
foal
foal
except
e
duran
five
foal
diarrhea
foal
without
diarrhea
classifi
cultur
posit
e
duran
frequenc
c
perfringen
c
difficl
pathogen
similar
foal
affect
affect
diarrhea
prospect
case
seri
undertaken
determin
associ
equin
theiler
diseas
hors
recruit
acvim
listserv
januari
inclus
criteria
acut
onset
clinic
sign
hepat
failur
laboratori
andor
liver
histopatholog
featur
characterist
theiler
diseas
aliquot
serum
liver
biolog
product
administ
case
test
eighteen
case
theiler
diseas
histori
biolog
product
administr
within
prior
month
receiv
tetanu
antitoxin
receiv
equin
plasma
receiv
allogen
stem
cell
ten
case
occur
histori
equin
biolog
product
administr
serum
andor
liver
consecut
case
biolog
product
case
aliquot
obtain
one
farm
case
investig
mare
virem
twenti
four
mare
pair
serum
chemistri
pcr
six
activ
hepat
normal
liver
enzym
fourteen
mare
persist
infect
year
without
clinic
diseas
conclus
consecut
case
theiler
diseas
infect
infect
also
common
hors
subclin
hepat
clinic
healthi
hors
find
suggest
fulmin
hepat
import
rare
outcom
infect
studi
perform
definit
prove
caus
theiler
diseas
epm
seriou
neurolog
diseas
hors
object
studi
assess
tempor
chang
proport
case
report
veterinari
teach
hospit
north
america
b
assess
percept
veterinari
practition
regard
incid
epm
past
year
medic
record
extract
veterinari
medic
data
base
vmdb
proport
morbid
rate
pmr
epm
comput
compar
across
breed
age
year
onlin
survey
veterinari
practition
conduct
januari
march
assess
equin
practition
percept
regard
pmr
epm
practic
area
pmr
signific
decreas
pmr
observ
year
studi
standardbr
walk
hors
thoroughbr
significantli
p
higher
pmr
compar
pmr
breed
major
practition
thought
incid
epm
chang
increas
previou
year
pmr
epm
hors
chang
howev
past
year
number
epm
case
present
veterinari
teach
hospit
significantli
decreas
note
significantli
decreas
pmr
contrast
practition
percept
major
thought
case
stay
increas
also
appear
standardbr
walk
hors
thoroughbr
geld
like
diagnos
epm
data
suggest
practition
treat
epm
field
fewer
case
refer
veterinari
teach
hospit
howev
data
interpret
caution
report
epm
case
vmdb
depend
veterinari
teach
hospit
assess
renal
function
includ
measur
serum
creatinin
cr
concentr
along
urin
specif
graviti
unfortun
cr
insensit
measur
loss
renal
function
also
affect
age
sex
muscl
mass
breed
serum
concentr
symmetr
dimethylarginin
sdma
recent
introduc
small
anim
practic
sensit
measur
assess
renal
function
valu
support
renal
diseas
sdma
also
report
less
affect
age
sex
breed
purpos
studi
measur
sdma
cohort
draft
hors
breed
well
assess
potenti
differ
age
sex
sdma
measur
use
proprietari
test
cr
measur
autom
chemistri
analyz
jugular
venou
blood
collect
healthi
draft
hors
includ
belgian
clydesdal
percheron
age
obtain
ownerstrain
sdma
valu
normal
distribut
cr
age
thu
median
valu
confid
interv
ci
determin
latter
data
analyz
use
anova
anova
rank
test
spearman
rank
order
correl
meanmedian
valu
age
sdma
cr
breed
found
tabl
median
age
differ
breed
signific
correl
age
sdma
cr
concentr
number
hors
year
age
small
n
also
differ
sdma
cr
concentr
sex
sdma
correl
cr
r
p
conclus
although
signific
differ
observ
sdma
concentr
draft
hors
breed
valu
less
upper
end
refer
rang
small
anim
absolut
differ
breed
small
evalu
sdma
concentr
hors
decreas
renal
perfus
renal
diseas
warrant
eosinophil
airway
diseas
ead
compon
inflammatori
airway
diseas
multisystem
eosinophil
epitheliotroph
diseas
syndrom
meed
howev
comprehens
studi
describ
ead
hors
medic
record
review
hors
receiv
bronchoalveolar
lavag
bal
hors
includ
hors
assign
three
group
base
bal
result
without
ead
eosinophil
mild
ead
eosinophil
ead
eosinophil
hors
group
eosinophil
bal
hors
group
like
mild
ead
hors
mast
cell
bal
mild
group
thorac
radiograph
reveal
sever
diffus
miliari
pattern
hors
ead
hors
pattern
lung
biopsi
eosinophil
infiltr
miner
deposit
fungal
hypha
eosinophil
inflamm
concurr
eosinophil
inflamm
affect
separ
organ
found
hors
mild
ead
ead
fecal
shed
strongyl
ova
low
ead
hors
eosinophil
airway
diseas
common
among
hors
clinic
sign
respiratori
diseas
studi
ead
associ
mastocyt
airway
inflamm
peripher
eosinophilia
occur
absenc
organ
involv
interstiti
lung
patholog
identifi
radiograph
histopatholog
canagliflozin
inhibitor
use
control
diabet
mellitu
human
octreotid
somatostatin
analog
prescrib
treatment
acromegali
hypothes
canagliflozin
octreotid
would
significantli
alter
glucos
insulin
concentr
hors
insulin
dysregul
id
without
neg
impact
health
six
hors
id
receiv
canagliflozin
octreotid
day
three
dosag
level
accord
crossov
design
plasma
glucos
insulin
concentr
measur
oral
sugar
test
ost
perform
prior
first
dose
hour
third
dose
drug
administ
advers
health
outcom
detect
drug
caus
insulin
concentr
decreas
immedi
follow
administr
ost
area
insulin
curv
auci
valu
compar
chang
significantli
low
canagliflozin
dosag
level
p
significantli
decreas
canagliflozin
treatment
medium
p
high
p
dosag
level
octreotid
auci
valu
differ
significantli
low
p
medium
p
dosag
level
significantli
increas
treatment
high
p
dosag
level
octreotid
transient
lower
insulin
concentr
hors
id
short
durat
action
provid
evid
canagliflozin
improv
insulin
dynam
hors
id
administr
dose
drug
warrant
investig
strategi
prevent
lamin
aberr
glucos
insulin
cortisol
acth
concentr
describ
rel
patholog
stress
respons
system
inflamm
result
insulin
cortisol
dysregul
mani
speci
howev
relationship
glucos
insulin
cortisol
acth
concentr
hors
system
inflammatori
respons
syndrom
sir
evalu
medic
record
adult
hors
undergo
emerg
admiss
auburn
univers
colorado
state
univers
plasma
acth
serum
insulin
glucos
cortisol
concentr
measur
review
hors
group
outcom
sir
surviv
correl
paramet
investig
p
consid
signific
one
hundr
hors
includ
surviv
diagnos
sir
overal
glucos
insulin
glucos
acth
acth
cortisol
posit
correl
n
p
n
p
n
respect
hors
sir
cortisol
glucos
posit
correl
n
p
hors
without
sir
glucos
insulin
posit
correl
n
p
survivor
glucos
insulin
posit
correl
n
p
trend
toward
posit
correl
glucos
acth
n
p
correl
observ
paramet
sir
result
hormon
dysregul
variabl
effect
axi
insulin
glucos
dynam
dysregul
would
sever
lac
proven
prognost
indic
commonli
measur
blood
equin
patient
increas
urinari
lac
urin
lac
creatinin
ratio
link
human
renal
diseas
neonat
hypox
ischem
encephalopathi
impact
hyperosmolar
nalac
infus
blood
urin
na
creatinin
concentr
investig
healthi
adult
hors
receiv
ml
salin
infus
iv
minut
contain
mmolkg
bwt
dose
nalac
result
rang
meq
total
na
lac
administ
blood
b
urin
u
sampl
prior
infus
time
minut
infus
start
lac
measur
blood
blac
urin
ulac
use
lactat
scout
within
minut
collect
urin
na
una
creatinin
ucr
una
ucr
ulac
ucr
ratio
usg
determin
data
assess
regress
analysi
anova
p
overal
serum
una
unrel
p
blood
lac
ulac
trend
toward
small
posit
associ
p
dose
significantli
impact
usg
usg
differ
mmolkg
bwt
lower
dose
differ
dose
impact
ucr
p
una
ucr
ulac
ucr
posit
associ
una
ulac
p
p
neg
associ
usg
p
p
una
ucr
ulac
ucr
posit
relat
p
p
usg
affect
na
load
impact
assess
ulac
ucr
una
cr
potenti
limit
nalac
challeng
studi
use
concentr
bodyweight
neuropath
pain
occur
lamin
larg
refractori
standard
analges
drug
may
control
drug
gabapentin
human
gabapentin
undergo
pharmacokinet
alter
safeti
efficaci
inform
pharmacokinet
escal
dosag
dose
proportion
gabapentin
hors
singl
blind
random
studi
use
adult
hors
receiv
gabapentin
administ
nasogastr
tube
hors
receiv
mgkg
hors
receiv
mgkg
plasma
collect
hour
post
administr
gabapentin
hors
washout
period
dose
gabapentin
quantifi
plasma
use
valid
chromatograph
method
pharmacokinet
paramet
estim
use
analysi
pharmacokinet
paramet
present
tabl
comput
simul
disposit
gabapentin
follow
oral
administr
predict
accumul
gabapentin
plasma
given
everi
hs
steadi
state
like
reach
day
dose
level
simul
plasma
concentr
gabapentin
oral
administr
present
figur
gabapentin
seem
increas
proport
mgkg
mgkg
rel
exposur
decreas
suggest
satur
extent
drug
absorpt
appar
chang
rate
elimin
drug
suggest
elimin
gabapentin
satur
higher
dose
gabapentin
colostr
immun
blood
selenium
se
level
often
insuffici
swiss
dairi
calv
data
avail
beef
calv
therefor
se
statu
beef
cow
newborn
calv
serum
gg
level
calv
investig
region
soil
blood
sampl
taken
cow
last
pregnanc
trimest
calv
day
age
beef
herd
determin
se
concentr
calv
igg
level
se
content
dri
cow
ration
roughag
miner
supplement
analyz
correl
logist
regress
test
serum
se
level
low
mgl
cow
calv
respect
signific
geograph
differ
serum
se
valu
cow
calv
significantli
correl
r
p
serum
gg
concentr
low
gl
indic
failur
passiv
transfer
calv
signific
correl
found
se
gg
concentr
r
p
roughag
sampl
low
se
content
mgkg
dri
matter
dm
mgkg
dm
none
mgkg
dm
complet
ration
miner
supplement
mgkg
dm
se
content
complet
ration
significantli
correl
cow
r
p
calv
r
p
serum
level
result
confirm
potenti
improv
se
suppli
colostr
manag
swiss
beef
herd
object
studi
observ
effect
extend
meloxicam
nsaid
therapi
alon
combin
therapi
develop
progress
clinic
ill
behavior
activ
individu
perform
paramet
lesion
sever
studi
conduct
random
control
trial
angu
steer
randomli
alloc
treatment
group
meloxicam
mel
mgkg
bw
everi
hour
treatment
ceftiofur
cef
excenel
rtu
mgkg
sq
everi
hour
treatment
meloxicam
ceftiofur
melcef
concord
dosag
rout
durat
therapi
con
bronchopneumonia
induc
deposit
x
cfu
mannheimia
haemolytica
osu
type
strain
care
giver
research
personnel
blind
treatment
calv
outfit
accelomet
rfid
tag
continu
behavior
feed
posit
data
captur
clinic
assess
rectal
temperatur
assess
twice
daili
rectal
temperatur
significantli
reduc
treatment
group
compar
control
calv
h
se
p
melcef
improv
feed
intak
hr
se
p
increas
averag
daili
gain
se
p
feed
convers
ratio
se
p
lie
time
increas
control
calv
se
p
conclus
meloxicam
combin
antimicrobi
improv
clinic
ill
behavior
econom
relev
perform
outcom
consid
import
adjunct
therapi
goal
studi
compar
cell
mediat
immun
respons
multipl
sourc
origin
calv
str
singl
sourc
calv
wean
day
un
peripher
blood
mononuclear
cell
pbmc
neutrophil
pmn
isol
blood
collect
via
jugular
vein
calf
pbmc
stimul
haemolytica
p
multocida
evalu
clonal
prolifer
secret
cell
cultur
supernat
function
capac
pmn
evalu
respons
stimul
aureu
antigen
sa
lipopolysaccharid
lp
peptidoglycan
pgn
complet
blood
count
cbc
serum
biochem
profil
perform
anim
time
sampl
collect
compar
str
calv
un
calv
significantli
greater
lymphocyt
prolif
respons
follow
stimul
viral
bacteri
antigen
p
addit
pmn
isol
un
calv
greater
abil
phagocytos
e
coli
aureu
compar
str
calv
serum
fatti
acid
nefa
significantli
higher
str
calv
p
serum
bhb
significantli
lower
str
calv
p
data
suggest
immunolog
physiolog
differ
exist
str
un
calv
underli
mechan
differ
clear
possibl
combin
energi
imbal
immunosuppress
gener
immun
may
predispos
str
calv
increas
risk
morbid
mortal
due
bovin
respiratori
diseas
goal
studi
compar
efficaci
tulathromycin
enrofloxacin
cattl
develop
brd
preval
mdr
strain
haemolytica
metaphylact
administr
drug
stocker
calv
randomli
assign
treatment
group
enrofloxacin
tulathromycin
calv
receiv
enrofloxacin
requir
treatment
brd
within
day
arriv
compar
calv
receiv
tulathromycin
odd
diagnos
brd
lower
calv
receiv
tulathromycin
compar
receiv
enrofloxacin
p
calv
receiv
enrofloxacin
requir
one
treatment
compar
calv
receiv
tulathromycin
odd
requir
second
treatment
lower
calv
receiv
tulathromycin
compar
receiv
enrofloxacin
p
calv
receiv
enrofloxacin
die
period
compar
calv
receiv
tulathromycin
p
calv
receiv
enrofloxacin
haemolytica
cultur
calv
sampl
arriv
sampl
revaccin
calv
receiv
tulathromycin
haemolytica
cultur
calv
sampl
arriv
sampl
revaccin
signific
effect
sampl
occas
p
group
higher
preval
haemolytica
revaccin
arriv
calv
group
mdr
strain
time
revaccin
preval
significantli
p
higher
arriv
tulathromycin
macrolid
antibiot
use
treatment
respiratori
diseas
multipl
speci
current
label
formul
tulathromycin
use
cattl
pig
formul
treatment
respiratori
diseas
goat
although
infecti
diseas
shown
alter
disposit
kinet
variou
drug
multipl
speci
current
data
avail
describ
pharmacokinet
tulathromycin
goat
respiratori
diseas
primari
object
studi
determin
pharmacokinet
pk
subcutan
inject
tulathromycin
goat
respiratori
diseas
compar
disposit
kinet
tulathromycin
healthi
goat
addit
object
compar
tissu
residu
level
healthi
vs
diseas
anim
twelv
commerci
femal
boer
goat
randomli
alloc
group
control
vs
experiment
experiment
group
challeng
via
intra
tracheal
intranas
administr
pasteurella
multocida
goat
administ
mgkg
subcutan
bolu
dose
tulathromycin
plasma
concentr
tulathromcyin
determin
initi
analysi
control
goat
yield
median
maximum
concentr
ugml
lambda
z
hr
experiment
goat
yield
maximum
concentr
ugml
lambda
z
hr
advers
effect
note
drug
administr
clinician
awar
potenti
pharmacokinet
variat
tulathromycin
goat
respiratori
diseas
thorac
ultrasonographi
tu
use
assess
extend
sever
lung
lesion
associ
bronchopneumonia
bp
feedlot
cattl
howev
littl
known
agreement
abnorm
tu
find
hypothesi
abnorm
tu
find
agreement
even
tu
perform
oper
differ
level
tu
expertis
random
sampl
tu
record
video
obtain
newli
receiv
feedlot
steer
without
clinic
sign
bp
score
differ
oper
differ
level
tu
expertis
follow
lesion
score
artifact
pleural
irregular
effus
lung
consolid
agreement
assess
use
kappa
fleiss
kappa
extend
multipl
oper
gwet
agreement
coeffici
chanc
correct
agreement
consid
adequ
median
interquartil
rang
cohen
differ
oper
presenc
pleural
irregular
pleural
effus
lung
consolid
fleiss
ci
pleural
irregular
pleural
effus
lung
consolid
pleural
irregular
pleural
effus
lung
consolid
conclus
lung
consolid
accept
agreement
oper
variou
level
tu
expertis
saluki
puppi
present
seizur
behavior
abnorm
month
age
abnorm
neurolog
examin
includ
gener
ataxia
thorac
limb
hypermetria
urin
acid
normal
markedli
elev
serum
cerebrospin
fluid
csf
succin
semialdehyd
markedli
elev
urin
csf
mri
show
diffus
mark
reduct
cerebr
cortex
thick
symmetr
hyperintens
deep
cerebellar
nuclei
intern
capsul
thalam
nuclei
tract
substantia
nigra
globu
pallidu
necropsi
cerebr
cortic
atrophi
vacuol
within
deep
cortic
grey
matter
subcort
white
matter
cerebrum
brain
succin
semialdehyd
activ
defici
base
pedigre
analysi
one
famili
recess
mode
inherit
assum
genom
wide
associ
analysi
perform
use
affect
dog
neurolog
normal
breed
match
control
illumina
canin
hd
array
genom
wide
signific
associ
base
pbonferroni
cfa
praw
identifi
mb
region
homozygos
case
underli
associ
whole
genom
sequenc
case
unaffect
control
variou
breed
investig
associ
interv
missens
mutat
gene
consid
compel
candid
gene
segreg
case
famili
predict
deleteri
larg
anim
model
may
provid
opportun
evalu
potenti
gene
therapi
rare
orphan
diseas
peopl
studi
shown
cerebrospin
fluid
csf
lactat
elev
human
patient
varieti
neurolog
condit
includ
inflammatori
central
nervou
system
cn
disord
neurodegen
diseas
seizur
activ
csf
lactat
shown
particularli
use
differenti
bacteri
steril
mening
purpos
studi
evalu
util
csf
lactat
biomark
canin
cn
diseas
first
valid
portabl
lactat
meter
requir
small
sampl
volum
analysi
canin
blood
subsequ
canin
csf
develop
refer
interv
canin
csf
mmoll
analyz
use
evalu
csf
sampl
dog
varieti
cn
disord
analyz
approxim
canin
csf
sampl
date
dog
meningoenceph
meningomyel
like
increas
csf
lactat
concentr
sampl
confirm
suspect
bacteri
mening
show
elev
concentr
although
mani
inflammatori
sampl
similarli
elev
mean
csf
lactat
concentr
cn
disord
group
broad
categori
inflammatori
diseas
mmoll
neoplast
diseas
mmoll
vascular
accid
mmoll
intervertebr
disk
diseas
mmoll
seizur
activ
seem
influenc
csf
lactat
concentr
analyz
use
rapid
analysi
lactat
canin
csf
elev
csf
lactat
frequent
attribut
inflammatori
cn
condit
may
aid
clinician
decid
acut
intervent
patient
cervic
spondylomyelopathi
csm
challeng
diseas
although
seen
progress
mani
aspect
relat
pathogenesi
diagnosi
advanc
treatment
hinder
lack
understand
progress
diseas
report
magnet
reson
imag
mri
investig
vertebr
spinal
cord
chang
dog
csm
eight
dog
month
initi
diagnosi
seven
dog
manag
medic
one
surgic
dorsal
laminectomi
two
site
stenot
site
evalu
first
mri
review
determin
characterist
compress
lesion
spinal
cord
signal
chang
mean
age
diagnosi
year
year
eight
dog
six
great
dane
seven
male
mean
median
mri
time
month
respect
main
direct
compress
lesion
dorsal
four
dog
dorsolater
two
dog
later
two
dog
evalu
compress
lesion
worsen
four
dog
improv
two
remain
unchang
two
two
dog
develop
extradur
synovi
cyst
caus
spinal
cord
compress
one
dog
develop
new
compress
lesion
worsen
two
dog
appear
new
site
spinal
cord
hyperintens
two
dog
seen
mri
find
studi
indic
cours
variabl
half
dog
show
progress
compress
lesion
spinal
cord
hyperintens
data
known
pathophysiolog
irradi
canin
brain
glioma
case
seri
describ
four
dog
develop
spinal
spread
brain
glioma
two
french
bulldog
male
old
boxer
femal
old
labrador
retriev
femal
old
diagnos
basi
magnet
reson
imag
mri
presum
superfici
grade
iii
oligodendroglioma
piriformi
lobe
treat
cur
intent
stereotact
volumetr
modul
arc
radiotherapi
day
end
irradi
develop
progress
head
neck
pain
mri
despit
complet
respons
primari
site
show
previous
absent
diffus
spinal
cord
enlarg
diffus
mening
thicken
contrast
enhanc
hydrocephali
hydrosyringomyelia
dog
euthanis
due
progress
worsen
clinic
condit
histopatholog
examin
diffus
deep
leptomening
glial
neoplast
infiltr
spinal
cord
detect
microscop
find
suggest
neoplast
glial
cell
either
drop
spinal
mening
cerebrospin
fluid
transit
along
white
matter
spinal
spread
brain
glioma
rare
condit
human
medicin
never
describ
dog
studi
could
highlight
stereotact
irradi
could
promot
spinal
spread
loos
arrang
neoplast
cell
superfici
oligodendroglioma
purpos
studi
compar
serum
phenobarbit
concentr
caregiv
satisfact
oral
po
transderm
td
administr
phenobarbit
pb
epilept
cat
nine
cat
enrol
prospect
cohort
studi
cat
receiv
week
follow
week
although
blood
concentr
expect
day
trial
continu
week
phase
observ
caregiv
satisfact
client
complet
questionnair
week
median
oral
pb
dosag
mgkgday
divid
mgkg
median
concentr
mcgml
mcgml
median
start
dosag
mgkgday
divid
mgkgday
first
td
concentr
mcgml
mcgml
one
cat
detect
concentr
td
concentr
within
final
po
concentr
p
administr
design
easi
po
td
phase
time
respect
howev
signific
differ
prefer
two
rout
administr
p
result
studi
indic
concentr
achiev
cat
follow
transderm
oral
administr
caregiv
report
greater
eas
administr
transderm
formul
purpos
studi
determin
pharmacokinet
biolog
effect
cytarabin
ocfosf
co
dog
co
oral
administ
prodrug
cytosin
arabinosid
nucleosid
analogu
use
treatment
inflammatori
brain
diseas
must
given
parenter
limit
use
three
healthi
dog
receiv
co
oral
everi
hour
dose
serum
obtain
day
administr
first
dose
cerebrospin
fluid
csf
obtain
co
concentr
measur
use
hplc
complet
blood
count
measur
leukocyt
valu
day
intranuclear
metabolit
measur
leukocyt
dna
maxim
serum
co
concentr
ngml
h
maxim
serum
concentr
ngml
h
co
detect
csf
hour
one
dog
hour
two
dog
detect
hour
dog
dog
becam
leukopen
receiv
dose
co
h
maxim
concentr
detect
leukocyt
dna
h
serum
concentr
follow
co
administr
lower
report
follow
parenter
administr
co
abl
enter
csf
peripher
blood
leukocyt
concentr
decreas
significantli
follow
administr
co
accumul
within
leukocyt
dna
convent
analysi
clinic
trial
compar
averag
outcom
treat
control
group
may
overlook
import
respons
specif
individu
recognit
respond
individu
also
provid
mean
retrospect
identifi
possibl
prognost
indic
outcom
assess
method
contain
inher
variabl
owe
error
measur
differ
within
individu
analyz
untreat
anim
use
method
deriv
laboratori
medicin
combin
defin
boundari
outcom
beyond
real
chang
attribut
intervent
infer
two
recent
clinic
trial
put
therapi
chronic
spinal
cord
injuri
companion
dog
benefit
group
level
data
untreat
control
describ
identifi
recipi
intraspin
olfactori
ensheath
cell
dog
receiv
intraspin
chondroitinas
unequivoc
respond
specif
clinic
characterist
common
amongst
dog
except
becam
paralyz
follow
intervertebr
disc
herniat
respond
rate
case
overal
correspond
nnt
although
nnt
appear
high
compar
associ
mani
commonli
use
drug
treat
condit
extrem
sever
avail
therapi
analysi
confirm
efficaci
two
intervent
sever
chronic
spinal
cord
injuri
dog
defin
respond
rate
although
success
provid
method
identifi
prognost
factor
respons
therapi
acut
thoracolumbar
spinal
cord
injuri
tlsci
common
dog
diffus
tensor
imag
dti
quantifi
microstructur
lesion
characterist
optim
time
examin
injuri
dog
unknown
object
investig
impact
durat
injuri
dti
imag
paramet
associ
clinic
sever
dog
acut
tlsci
variabl
sever
underw
dti
includ
fraction
anisotropi
fa
mean
diffus
md
calcul
region
interest
cranial
caudal
within
lesion
epicent
relationship
fa
md
valu
durat
injuri
imag
interv
clinic
neurolog
grade
determin
use
regress
analysi
wilcoxon
rank
sum
mean
age
year
median
durat
day
neurolog
grade
rang
grade
ii
ambulatori
paraparesi
v
paraplegia
absent
pain
percept
mean
fa
cranial
lesion
epicent
caudal
mean
md
cranial
epicent
caudal
account
neurolog
grade
fa
cranial
caudal
invers
associ
durat
p
relationship
identifi
fa
grade
differ
time
point
day
day
day
md
cranial
caudal
invers
associ
grade
amongst
dog
imag
within
hour
p
durat
injuri
consid
interpret
dti
result
dog
acut
tlsci
variabl
relationship
injuri
sever
dti
indic
acut
set
goal
cancer
treatment
dog
increas
surviv
provid
good
qualiti
life
qol
prospect
blind
random
control
studi
investig
whether
novel
dri
diet
increas
protein
antioxid
custom
fiber
blend
epa
dha
would
improv
qol
compar
typic
mainten
diet
dog
undergo
chemotherapi
lymphoma
lsa
mast
cell
tumor
mct
dog
lsa
mct
enrol
mainten
diet
group
lsa
mct
test
diet
group
dog
ate
diet
week
treat
standard
chemotherapi
protocol
specif
tumor
type
five
studi
site
dog
owner
evalu
qol
baselin
week
use
previous
publish
questionnair
design
dog
cancer
data
analyz
use
intent
treat
principl
signific
differ
dog
tumor
paramet
diet
group
baselin
bodi
weight
dog
test
diet
weigh
dog
mainten
diet
kg
p
fourteen
lsa
mct
dog
mainten
group
dog
lsa
mct
test
group
complet
studi
p
baselin
week
qol
paramet
significantli
improv
dog
test
diet
improv
dog
eat
mainten
diet
dog
test
diet
improv
sign
ill
dog
mainten
diet
p
qol
differ
diet
group
although
statist
power
limit
small
sampl
size
studi
suggest
diet
chemotherapi
could
play
role
qol
investig
warrant
phase
clinic
trial
evalu
safeti
effect
proprietari
liquid
fiduci
defin
clinic
target
volum
ctv
patient
margin
resect
tumor
skin
subcutan
tissu
clinic
target
volum
use
defin
plan
target
volum
ptv
purpos
deliv
singl
fraction
stereotact
radiat
sr
resect
bed
form
cur
intent
therapi
thirti
patient
enter
phase
trial
elig
patient
must
incomplet
resect
tumor
skin
subcutan
tissu
neg
stage
system
diseas
entri
criterion
signific
comorbid
similarli
exclusionari
inject
interv
along
resect
scar
volum
use
inject
site
follow
inject
sr
immobil
creat
ct
simul
done
purpos
radiotherapi
plan
ctv
defin
interpol
fiduci
inject
site
creat
tubular
volum
ptv
expans
intend
incorpor
region
margin
resect
appli
ctv
plan
gener
deliv
singl
stereotact
dose
patient
monitor
acut
delay
toxic
well
overal
surviv
signific
advers
event
note
phase
patient
either
inject
deliveri
singl
fraction
sr
fiduci
visibl
could
use
gener
ctv
patient
acut
radiat
toxic
observ
delay
toxic
score
base
vrtog
morbid
score
scheme
date
earli
failur
geograph
miss
cohort
patient
patient
remain
clinic
remiss
result
studi
suggest
use
liquid
fiduci
creat
plan
target
volum
sr
deliveri
safe
minim
acut
delay
toxic
observ
addit
patient
inject
fiduci
easili
identifi
marker
present
could
use
ctvptv
creation
treatment
align
purpos
use
cone
beam
ct
linear
acceler
base
result
trial
expand
focu
outcom
toxic
analysi
base
specif
tumor
type
pathway
implic
tumor
growth
surviv
metastasi
commonli
dysregul
veterinari
human
cancer
sever
inhibitor
pathway
fda
approv
treatment
human
neoplasia
none
approv
veterinari
set
inhibitor
alpha
valu
nm
nm
inhibit
human
alpha
mtor
respect
biochem
kinas
assay
approxim
less
activ
delta
gamma
isoform
vitro
data
suggest
antiproliferativeantimetastat
activ
sever
tumor
type
includ
lymphoma
osteosarcoma
hemangiosarcoma
develop
potenti
therapeut
candid
veterinari
cancer
goal
studi
determin
maximum
toler
dose
dose
limit
toxic
pharmacokinet
dog
spontan
cancer
mean
clinic
trial
dog
histolog
confirm
malign
neoplasia
receiv
escal
oral
dose
either
administ
daili
daili
monday
friday
week
plasma
pharmacokinet
analysi
perform
follow
first
dose
tumor
drug
concentr
measur
subset
dog
hour
first
dose
respons
assess
advers
event
evalu
perform
use
vcog
criteria
dog
prospect
enrol
initi
dose
cohort
enrol
dose
mgkg
daili
subsequ
cohort
receiv
mgkg
daili
mtd
determin
mgkg
stomat
dlt
linear
relationship
administ
dose
drug
exposur
signific
drug
accumul
observ
tumor
tissu
object
respons
observ
dog
lymphoma
dog
mast
cell
tumor
dog
squamou
cell
carcinoma
conclus
establish
optim
dose
mgkg
evalu
subsequ
prospect
studi
surgic
adjuv
studi
dog
splenic
hemangiosarcoma
current
ongo
current
lymphoma
therapi
induc
remiss
dog
relaps
common
creat
need
novel
agent
rabacfosadin
doubl
prodrug
acycl
nucleotid
phosphon
pmeg
preferenti
target
lymphoma
cell
reduc
system
toxic
compar
pmeg
previou
studi
evalu
rabacfosadin
everi
day
suggest
efficaci
relaps
subject
howev
larg
studi
rabacfosadin
singl
agent
report
previous
untreat
canin
lymphoma
patient
evalu
rabacfosadin
safeti
efficaci
dog
previous
untreat
lymphoma
treat
part
previou
prospect
studi
dog
previous
untreat
lymphoma
receiv
five
rabacfosadin
treatment
everi
day
mgkg
mgkg
min
iv
infus
without
concurr
prednison
respons
assess
advers
event
evalu
perform
everi
day
via
vcog
criteria
overal
respons
rate
orr
cr
pr
overal
median
progress
free
interv
pfi
day
cr
pr
respond
cell
immunophenotyp
hr
prednison
hr
predict
inferior
pfi
administ
dose
signific
predictor
orr
pfi
advers
event
commonli
gastrointestin
origin
hyporexiadiarrhea
gener
resolv
support
treatment
andor
dosag
adjust
two
dog
experienc
grade
delay
pulmonari
fibrosi
conclus
rabacfosadin
administ
everi
three
week
gener
demonstr
substanti
antitumor
activ
dog
previous
untreat
lymphoma
mycobacterium
cell
wall
fraction
mcwf
immunomodul
deriv
mycobacterium
mycobacterium
phlei
current
licens
canada
usa
treatment
mix
mammari
tumor
mammari
adenocarcinoma
dog
market
mcwf
use
treatment
malign
osteosarcoma
transit
cell
carcinoma
soft
tissu
sarcoma
hemangiosarcoma
transit
vener
tumor
dog
mcwf
consid
bifunct
anticanc
agent
induc
apoptosi
cancer
cell
stimul
cytokin
chemokin
synthesi
immun
system
cell
purpos
present
research
assess
clinic
safeti
profil
follow
multipl
intraven
administr
cat
dog
variou
malign
addit
explor
immunomodulatori
potenti
effect
adjunct
treatment
oncolog
standard
care
treatment
variou
neoplasia
dog
cat
prior
start
studi
experiment
protocol
review
approv
institut
anim
care
use
committe
studi
singl
site
specif
clinic
conduct
oncolog
referr
clinic
veterinari
cancer
care
santa
fe
new
mexico
usa
inclus
criteria
studi
life
expect
minimum
week
confirm
neoplasia
histolog
cytolog
concurr
radiat
steroid
therapi
total
patient
enrol
studi
patient
enrol
studi
follow
tumor
type
mast
cell
tumor
canin
thyroid
carcinoma
canin
high
grade
soft
tissu
sarcoma
canin
lymphoma
canin
felin
fibrosarcoma
canin
osteosarcoma
canin
inject
site
sarcoma
felin
oral
melanoma
canin
anal
gland
adenocarcinoma
canin
transit
cell
carcinoma
canin
hemangiosarcoma
canin
mammari
adenocarcinoma
canin
histiocyt
sarcoma
canin
pulmonari
carcinoma
canin
multipl
myeloma
canin
pheochromocytoma
canin
mcwf
emuls
suppli
novav
inc
canada
vial
mcwf
contain
concentr
dosag
administ
follow
rang
prior
administr
dose
dilut
steril
nacl
administ
intraven
minut
treatment
perform
either
weekli
everi
week
depend
standard
chemotherapi
protocol
anal
glad
carcinoma
patient
treat
everi
week
combin
carboplatin
treatment
patient
also
diphenhydramin
dog
cat
treat
studi
use
administr
protocol
administr
perform
day
follow
standard
chemotherapi
dose
one
follow
vincristin
doxorubicin
dacarbazin
carboplatin
accord
standard
treatment
protocol
follow
administr
mcwf
anim
close
monitor
clinic
sent
home
owner
temperatur
blood
pressur
heart
respiratori
rate
assess
everi
min
addit
whole
blood
sampl
taken
everi
two
four
week
complet
blood
count
clinic
chemistri
analysi
perform
advers
event
ae
observ
anim
consid
minim
observ
ae
includ
mild
lethargi
mild
transient
hyperthermia
observ
patient
within
hour
mcwf
administr
resolv
within
hour
one
canin
patient
hyperthermia
f
vomit
resolv
within
hour
diphenhydramin
cerenia
maropit
citrat
requir
prednison
clinic
relev
hematolog
chang
observ
mcwf
use
combin
standard
chemotherapi
protocol
sever
case
inject
site
sarcoma
histiocyt
sarcoma
osteosarcoma
measur
pulmonari
metastasi
remain
stabl
show
regress
radiograph
current
observ
safeti
follow
intraven
administr
clinic
impress
cat
dog
variou
neoplasisa
satisfactori
provid
solid
base
futur
research
addit
control
clinic
studi
plan
demonstr
efficaci
conjunct
therapi
standard
care
treatment
hemangiosarcoma
soft
tissu
sarcoma
overal
present
data
show
clinic
set
mcwf
immunomodulatori
potenti
play
role
treat
addit
neoplasia
beyond
mammari
tumor
adjunct
treatment
combin
standard
protocol
evalu
advers
event
qualiti
life
metastat
progress
surviv
dog
appendicular
osteosarcoma
treat
amput
toceranib
dog
appendicular
osteosarcoma
radiograph
pulmonari
metastasi
prospect
enrol
clinic
trial
follow
limb
amput
dog
prescrib
oral
toceranib
mgkg
famotidin
blood
exam
paramet
collect
weekli
week
monthli
year
month
thorac
radiograph
perform
everi
month
qualiti
life
symptom
measur
visit
use
valid
questionnair
dog
follow
death
underw
necropsi
dog
mean
age
year
mean
weight
kg
enrol
mean
start
toceranib
dose
mgkg
mean
treatment
durat
day
dose
reduct
temporari
treatment
break
occur
dog
dog
receiv
metronidazol
denamarin
manag
low
grade
diarrhea
liver
enzym
elev
respect
two
dog
seriou
advers
event
could
relat
treatment
median
progress
free
overal
surviv
time
day
ci
day
ci
respect
metastat
osteosarcoma
confirm
histopatholog
dog
metastasi
death
owner
consist
rate
qualiti
life
good
excel
throughout
treatment
although
rate
sometim
lower
period
advers
clinic
sign
combin
amput
oral
toceranib
associ
accept
qualiti
life
surviv
could
benefici
adjuv
treatment
intraven
chemotherapi
unavail
refus
owner
research
use
intestin
stem
cell
acceler
last
decad
allow
develop
cultur
system
support
epitheli
growth
intestin
organoid
term
enteroidscolonoid
entcol
tissu
repres
primari
epitheli
cultur
passag
indefinit
genet
stabl
time
make
invalu
tool
studi
stem
cell
physiolog
diseas
model
dog
previou
report
canin
entcol
shown
limit
cultur
abil
perform
diseas
anim
aim
studi
develop
cultur
protocol
duodenum
jejunum
ileum
colon
entcol
healthi
dog
dog
chronic
enteropathi
ce
addit
sought
extens
character
cell
within
entcol
use
bright
field
imag
transmiss
electron
microscopi
immunohistochemistri
rna
situ
hybrid
rna
microarray
function
assay
develop
use
transwel
cultur
approach
stimul
assay
optic
metabol
imag
omi
cultur
matrigel
organoid
cryopreserv
develop
canin
entcol
bioarchiv
ten
endoscop
biopsi
per
intestin
region
acquir
healthi
ce
dog
minc
sampl
repeatedli
wash
crypt
enrich
use
edta
chelat
releas
via
tritur
embed
matrigel
grown
intestin
stem
cell
media
organoid
yield
enteroidsbiopsi
colonoidsbiopsi
averag
optim
intestin
stem
cell
growth
media
prolifer
versu
differenti
contain
kinas
rock
inhibitor
glycogen
synthas
kinas
inhibitor
entcol
passag
weekli
month
show
differenti
entcol
primarili
stem
cell
cyst
day
chiefli
differenti
mosaic
intestin
stem
cell
enterocyt
goblet
cell
enteroendocrin
cell
cell
tuft
cell
day
depend
supplement
morpholog
characterist
appar
h
e
includ
prolifer
via
rel
abund
mitot
figur
classic
order
simpl
columnar
epitheli
polar
basal
nuclei
clear
cytoplasm
goblet
cell
ultrastructur
reveal
increas
densiti
tight
junction
day
day
entcol
function
analys
use
lp
stimul
entcol
show
markedli
increas
growth
rate
ileal
enteroid
versu
colonoid
differenti
mrna
express
profil
stimul
optic
metabol
imag
show
differ
metabol
activ
enteroid
ce
healthi
dog
first
report
success
propag
ex
vivo
canin
endoscop
procur
entcol
clinic
ce
patient
across
region
intestin
studi
lie
foundat
futur
tissu
engin
toxicolog
microbi
studi
therapeut
trial
acid
suppress
drug
commonli
prescrib
treatment
gastrointestin
ulcer
eros
gue
studi
dog
cat
omeprazol
shown
effect
rais
gastric
ph
recommend
gue
treatment
howev
famotidin
continu
wide
use
veterinari
practition
especi
condit
potent
acid
suppress
desir
dog
human
acid
suppress
effect
famotidin
decreas
time
often
within
week
everi
day
eod
famotidin
administr
might
prevent
induct
toler
studi
object
determin
daili
famotidin
administr
lead
toler
cat
eod
administr
prevent
induct
toler
random
crossov
studi
cat
receiv
mgkg
famotidin
oral
daili
eod
week
intragastr
ph
compar
treatment
day
within
treatment
use
repeat
measur
mix
effect
anova
continu
famotidin
administr
result
signific
decreas
mean
ph
mean
percentag
time
mpt
intragastr
ph
mpt
intragastr
ph
p
treatment
day
compar
day
cat
receiv
daili
famotidin
receiv
eod
result
mean
decreas
ph
day
compar
day
furthermor
mean
decreas
mpt
mpt
observ
time
period
respect
repeat
oral
famotidin
administr
result
diminish
effect
gastric
ph
cat
weak
effect
famotidin
prevent
administ
drug
eod
limit
use
day
durat
radioiodin
treatment
choic
felin
hyperthyroid
optim
method
determin
radioiodin
dose
controversi
standard
eg
mci
eg
mci
protocol
use
often
clinician
result
resolut
hyperthyroid
cat
howev
protocol
littl
regard
develop
iatrogen
hypothyroid
protocol
cat
present
mild
moder
hyperthyroid
subsequ
develop
overt
subclin
iatrogen
hypothyroid
j
vet
intern
med
consequ
iatrogen
hypothyroid
manifest
worsen
unmask
kidney
diseas
rapid
progress
kidney
diseas
shorten
surviv
time
cat
ckd
therefor
individu
protocol
determin
lowest
possibl
radioiodin
dose
resolv
hyperthyroid
without
induc
iatrogen
hypothyroid
provid
better
outcom
client
cat
sought
develop
object
method
determin
dose
cat
individu
would
result
resolut
hyperthyroid
minim
risk
iatrogen
hypothyroid
base
result
serum
thyroid
hormon
concentr
quantit
thyroid
scintigraphi
thyroid
uptak
administ
radioiodin
prospect
studi
includ
cat
median
age
year
refer
anim
endocrin
clinic
treatment
septemb
septemb
cat
treat
methimazol
methimazol
discontinu
week
prior
evalu
treatment
cat
baselin
serum
concentr
tsh
j
vet
intern
med
determin
quantit
thyroid
scintigraphi
perform
sodium
subsequ
calcul
cat
thyroid
volum
percent
thyroid
uptak
tctu
previous
describ
vet
radiol
ultrasound
cat
receiv
initi
low
radioiodin
dose
mci
subcutan
hour
later
measur
radioact
thyroid
tumor
extern
count
ludlum
survey
meter
determin
percent
uptak
administ
radioiodin
dose
thyroid
tumor
develop
novel
algorithm
base
final
dose
follow
paramet
serum
concentr
tctu
calcul
thyroid
volum
radioiodin
uptak
algorithm
final
dose
also
adjust
deliv
radiat
dose
gm
thyroid
tumor
tissu
need
addit
radioiodin
dose
administ
day
order
provid
enough
radioiodin
meet
final
calcul
dose
treatment
recheck
examin
perform
month
serum
concentr
tsh
creatinin
determin
visit
analysi
cat
classifi
thyroid
categori
euthyroid
tsh
ngml
overt
hypothyroid
tsh
ngml
subclin
hypothyroid
tsh
ngml
persist
hyperthyroid
tsh
ngml
median
calcul
dose
administ
mci
interquartil
rang
iqr
mci
rang
mci
cat
receiv
radioiodin
dose
mci
treat
cat
cat
becam
euthyroid
cat
develop
overt
hypothyroid
cat
becam
subclin
hypothyroid
cat
remain
hyperthyroid
preval
azotemia
significantli
higher
p
cat
overt
subclin
hypothyroid
cat
remain
euthyroid
radioiodin
treatment
conclus
novel
algorithm
calcul
individu
dose
base
serum
thyroid
hormon
concentr
thyroid
scintigraphi
thyroid
tumor
volum
percent
tctu
radioiodin
uptak
thyroid
tumor
result
cure
rate
similar
histor
rate
dramat
reduc
incid
overt
subclin
hypothyroid
importantli
lower
calcul
radioiodin
dose
compar
current
administ
protocol
limit
radiat
exposur
veterinari
staff
owner
final
lower
incid
iatrogen
hypothyroid
individu
approach
also
lower
rate
azotemia
develop
radioiodin
treatment
glucagon
respons
hypoglycemia
iih
often
impair
diabet
mellitu
dm
howev
mechan
lead
impair
dog
diabet
unknown
glucagon
norepinephrin
epinephrin
cortisol
respons
iih
studi
dog
natur
occur
dm
healthi
control
dog
fast
overnight
diabet
insulin
withheld
hour
studi
hypoglycemia
induc
intraven
infus
regular
porcin
insulin
mukgmin
clamp
mean
sd
mgdl
use
variabl
rate
glucos
infus
hormon
measur
min
interv
mean
hormon
concentr
iih
consecut
time
point
divid
concentr
euglycemia
calcul
fold
increas
dog
data
normal
distribut
comparison
perform
test
norepinephrin
respons
iih
reduc
diabet
vs
control
dog
median
rang
fold
increas
vs
respect
p
divid
base
glucagon
respons
iih
diabet
dog
impair
glucagon
respons
n
also
lower
norepinephrin
respons
fold
compar
control
p
dog
normal
glucagon
respons
n
differ
control
dog
norepinephrin
respons
iih
fold
increas
p
signific
differ
epinephrin
cortisol
respons
iih
diabet
control
dog
sympathet
activ
iih
decreas
dm
dog
could
contribut
impair
glucagon
secret
role
inadequ
hypoglycem
counterregul
canin
idiopath
megaesophagu
guardedgrav
prognosi
human
lower
esophag
sphincter
le
achalasia
character
failur
le
relax
respons
pharyng
swallow
caus
respond
target
intervent
inject
botulinum
toxin
bta
mechan
dilat
pneumaticbougienag
surgic
myotomi
reliev
function
le
obstruct
studi
object
evalu
target
therapi
canin
le
syndrom
lal
fourteen
dog
lal
identifi
via
unrestrain
videofluoroscop
swallow
studi
vfss
lack
endoscop
intralumin
obstruct
posit
respons
bta
inject
le
dilat
posit
respons
defin
reduc
regurgit
frequenc
increas
bodi
weight
bw
bodi
condit
score
bc
scale
vfss
improv
esophag
empti
data
report
median
iqr
dog
posit
respons
candid
le
myotomi
dog
respond
improv
vfss
le
achalasia
diminish
regurgit
increas
bcsweight
note
within
week
percent
reduct
regurgit
increas
bw
respect
bc
respect
durat
effect
day
six
dog
subsequ
underw
myotomi
clinic
improv
despit
clinic
improv
persist
note
dog
follow
month
dog
lal
demonstr
temporari
clinic
improv
target
intervent
suggest
potenti
diagnost
therapi
subpopul
dog
preliminari
result
suggest
myotomi
provid
last
clinic
benefit
despit
persist
due
relief
function
le
obstruct
induc
nitric
oxid
synthas
ino
present
kidney
normal
condit
upregul
respons
inflamm
although
normal
protect
upregul
ino
subsequ
overproduct
nitric
oxid
nitros
stress
maladapt
associ
cytotox
effect
progress
vascular
dysfunct
oxid
stress
telomer
shorten
felin
chronic
kidney
diseas
ckd
character
tubulointerstiti
inflamm
associ
oxid
stress
telomer
shorten
purpos
studi
character
ino
express
kidney
ckd
cat
comparison
young
geriatr
cat
without
clinic
evid
renal
dysfunct
hypothesi
ino
upregul
tubul
cat
ckd
ino
assess
kidney
tissu
collect
autopsi
ckd
cat
iri
stage
cat
iri
stage
cat
iri
stage
cat
young
control
year
geriatr
control
year
ckd
cat
substag
presenc
hypertens
proteinuria
doubl
label
immunohistochemistri
ino
perform
kidney
cross
section
assess
cortic
vs
corticomedullari
express
consecut
high
power
field
region
examin
score
separ
pathologist
blind
clinic
data
within
field
tubul
design
either
ino
label
tubul
score
posit
neg
intens
tubular
ino
express
also
evalu
assign
numer
score
neg
mild
moder
heavi
field
percent
ino
posit
ino
intens
score
tubul
cortic
corticomedullari
region
compar
cohort
cat
use
dunn
post
hoc
analysi
expect
tubul
morpholog
consist
proxim
tubul
morpholog
consist
distal
tubul
median
percentag
tubul
ino
ino
cortex
ckd
cat
median
rang
significantli
increas
comparison
young
cat
median
rang
p
percentag
ino
proxim
tubulesin
cortex
geriatr
cat
median
rang
exhibit
trend
toward
statist
signific
comparison
young
normal
cat
p
statist
signific
differ
median
percentag
corticomedullari
ino
proxim
tubul
cortic
corticomedullari
ino
distal
tubul
group
although
intens
ino
express
variabl
signific
differ
intens
ino
stain
cortex
ckd
cat
comparison
young
normal
cat
p
cortex
corticomedullari
junction
group
ino
distal
tubul
increas
express
ino
comparison
ino
proxim
tubul
p
comparison
signific
differ
percentag
ino
express
observ
ckd
cat
without
hypertens
differ
iri
stage
despit
basal
express
ino
felin
kidney
particularli
distal
tubul
ino
express
increas
proxim
tubul
renal
cortex
ckd
cat
implic
increas
ino
express
felin
ckd
investig
provid
potenti
mechanist
insight
telomer
shorten
observ
kidney
ckd
cat
treatment
hyperthyroid
cat
frequent
associ
unmask
chronic
kidney
diseas
current
renal
biomark
reliabl
predict
develop
azotemia
occur
secondari
decreas
glomerular
filtrat
rate
gfr
follow
treatment
hyperthyroid
sdma
shown
sensit
marker
gfr
veterinari
medicin
influenc
chang
muscl
mass
hypothes
sdma
could
use
biomark
predict
decreas
total
gfr
onset
azotemia
cat
receiv
therapi
cat
diagnos
hyperthyroid
base
clinic
sign
increas
serum
total
includ
prospect
clinic
trial
studi
design
includ
physic
exam
complet
blood
count
serum
chemistri
total
urinalysi
sdma
prior
treatment
month
addit
gfr
quantifi
renal
scintigraphi
immedi
prior
month
current
cat
enrol
trial
complet
diagnost
evalu
three
time
point
median
age
cat
year
rang
year
compris
neuter
male
spay
femal
cat
enrol
creatinin
mgdl
mean
decreas
significantli
one
three
month
p
five
cat
euthyroid
cat
hypothyroid
three
month
mean
total
gfr
p
mean
serum
creatinin
p
decreas
increas
significantli
time
point
respect
mean
serum
sdma
differ
significantli
baselin
p
p
month
signific
correl
found
sdma
either
total
gfr
r
p
base
result
conclud
serum
sdma
accur
reflect
chang
gfr
hyperthyroid
cat
result
support
use
sdma
predict
develop
azotemia
follow
therapi
prospect
random
multicent
studi
evalu
efficaci
telmisartan
cat
system
arteri
hypertens
ht
defin
mean
indirect
systol
blood
pressur
sbp
mmhg
document
two
occas
prior
enrol
cat
sbp
mmhg
evid
sever
target
organ
damag
exclud
hypertens
cat
randomli
assign
ratio
receiv
telmisartan
oral
solut
placebo
cat
administ
mg
telmisartankg
day
follow
mg
telmisartankg
sbp
measur
day
baselin
chang
sbp
compar
baselin
calcul
day
telmisartan
efficaci
defin
signific
reduct
sbp
day
compar
placebo
clinic
relev
mmhg
reduct
sbp
day
data
present
mean
ci
total
cat
includ
mean
sd
baselin
sbp
mmhg
mmhg
cat
respect
day
sbp
reduct
significantli
greater
mmhg
versu
mmhg
cat
p
day
telmisartan
therapi
result
clinic
relev
sbp
reduct
mmhg
wherea
placebo
mmhg
sbp
reduct
achiev
versu
group
telmisartan
decreas
sbp
statist
signific
clinic
relev
magnitud
well
toler
hypertens
cat
muscl
loss
common
diseas
age
difficult
quantit
assess
clinic
therefor
quantit
method
need
object
studi
evalu
ultrasound
techniqu
previous
valid
dog
vertebr
epaxi
muscl
score
vem
cat
healthi
neuter
cat
year
age
elig
mean
epaxi
muscl
height
calcul
three
transvers
ultrasound
imag
obtain
thorac
vertebra
use
linear
transduc
fourth
thorac
vertebr
length
measur
thorac
radiographi
ratio
epaxi
muscl
length
vem
calcul
compar
bodi
weight
ratio
epaxi
muscl
height
variou
zoometr
measur
also
compar
bodi
weight
potenti
altern
use
length
cat
enrol
mean
bodi
weight
kg
mean
epaxi
muscl
height
cm
significantli
correl
bodi
weight
r
p
vem
r
p
epaxi
muscl
height
forelimb
circumfer
r
p
correl
bodi
weight
vem
epaxi
muscl
heightfor
limb
circumfer
techniqu
normal
muscl
size
across
vari
bodi
weight
cat
studi
warrant
determin
whether
techniqu
accur
assess
muscl
cat
vari
adipos
muscl
loss
canin
babesiosi
diseas
caus
haemoprotozoan
parasit
genu
babesia
infect
erythrocyt
dog
diagnosi
complic
divers
babesia
speci
includ
babesia
cani
bca
b
voge
bv
b
rossi
br
b
gibsoni
bg
b
conrada
bco
speci
vari
pathogen
tick
vector
indic
treatment
geograph
distribut
speci
often
overlap
requir
accur
identif
involv
speci
manag
clinic
case
canin
babesiosi
observ
studi
aim
assess
region
variat
occurr
speciat
babesia
spp
infect
dog
base
result
global
canin
popul
test
singl
platform
pcr
assay
data
gather
intern
databas
result
canin
sampl
submit
commerci
refer
laboratori
babesia
pcr
test
reason
blood
sampl
posit
babesia
spp
genu
pcr
ssrrna
subsequ
test
use
pcr
assay
five
speci
b
cani
heat
shock
protein
b
voge
heat
shock
protein
b
rossi
heat
shock
protein
b
gibsoni
heat
shock
protein
b
conrada
overal
result
avail
analysi
base
sampl
submit
countri
group
six
region
sampl
test
posit
babesia
spp
genu
level
speciat
result
unavail
posit
sampl
due
insuffici
sampl
volum
remain
qn
follow
primari
genu
level
pcr
screen
remain
posit
sampl
speciat
follow
b
gibsoni
b
cani
b
voge
b
conrada
b
rossi
speci
could
determin
sampl
babesia
spp
pcr
posit
rate
speciat
result
region
summar
tabl
studi
repres
broadest
worldwid
pcr
survey
canin
babesiosi
report
date
util
data
singl
platform
result
highlight
signific
divers
region
variat
babesia
speci
infect
dog
global
addit
studi
need
character
babesia
spp
posit
sampl
could
speciat
understand
geograph
relev
